“23andMe’s business model has always depended on leveraging the DNA data they amass as a result.” The company has deals to sell DNA data to pharma co’s GlaxoSmithKline, Genentech, & Pfizer. https://t.co/sKM8ZiXZSK HT @BethSkw
"23andMe's business model has always depended on leveraging the DNA data they amass as a result." The company has deals to sell DNA data to pharma co's GlaxoSmithKline, Genentech, & Pfizer. https://t.co/sKM8ZiXZSK HT @BethSkw
— Joel Winston (@joelwinston) August 1, 2018
